7 completed. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 7 |
Follow COPD Exacerbation: new trials by email Literature Review of COPD Exacerbation trials Research Report on COPD Exacerbation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause Long acting muscarinic antagonists (LAMAs) in the evening - COPD Exacerbation | Phase 4 | Completed | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | 10011 | 2023-01-27 | 2025-02-19 |
| Eosinophil-guided Reduction of Inhaled Corticosteroids Azithromycin, ICS - COPD, Inhaled Corticosteroid | Phase 4 | Completed | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | 444 | 2021-06-28 | 2026-01-28 |
| Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) - COPD Exacerbation | Phase 4 | Completed | University of Tennessee Graduate School of Medicine | 60 | 2020-12-09 | 2026-08-03 |
| Stratified TreAtment to Reduce Risk in COPD Prednisolone - COPD Exacerbation | Phase 4 | Completed | University of Oxford | 203 | 2017-11-02 | 2020-07-21 |
| Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB) ceftidoren, levofloxacin - COPD Exacerbation | Phase 4 | Completed | University of Milan | 40 | 2012-01-01 | 2012-06-05 |
| Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Roflumilast, Placebo - COPD, COPD Exacerbation | Phase 4 | Completed | AstraZeneca | 2354 | 2011-09-30 | 2017-04-13 |
| Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD Levofloxacin 1 tablet 500 mg once a day, Prulifloxacin 1 tablet 600 mg once a day - COPD Exacerbation | Phase 4 | Completed | Fadoi Foundation, Italy | 258 | 2009-05-01 | 2025-02-11 |
Pulmonary Disease, Chronic Obstructive (2) · Bronchitis, Chronic (1) · Inflammation (1) · Lung Diseases (1) · Pneumonia (1) · Respiration Disorders (1)
Chronic Disease (3) · Disease Attributes (3) · Lung Diseases, Obstructive (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Respiratory Tract Diseases (3) · Infections (2) · Lung Diseases (2) · Respiratory Tract Infections (2) · Bronchial Diseases (1) · Bronchitis (1) · Pulmonary Disease, Chronic Obstructive (1)
Azithromycin (1) · Formoterol Fumarate (1) · Levofloxacin (1) · Prednisolone (1) · Roflumilast (1) · revefenacin (1)
Chronic Obstructive Pulmonary Disease Trial Network, Denmark (2) · AstraZeneca (1) · Fadoi Foundation, Italy (1) · University of Milan (1) · University of Oxford (1) · University of Tennessee Graduate School of Medicine (1)
Italy (3) · Denmark (2) · United States (2) · Argentina (1) · Canada (1) · Chile (1) · Colombia (1) · Malaysia (1) · Mexico (1) · Peru (1) · Philippines (1) · Romania (1) · Russia (1) · Serbia (1) · Spain (1)
Francesco B Blasi, MD (1) · Gualberto GG Gussoni, MD, PhD (1) · Mona Bafadhel, MBChB, PhD (1)
PMID 27585384, PMID 29579254, PMID 29763572, PMID 39165373, PMID 40898355, PMID 41340061, PMID 42548489